Startseite Kongressberichte 2020 Virtual Edition of the 25th Annual Congress of the European Hematology Association Oral Sessions Acute Leukemia AML: AML:

AML therapy

 
James D. Griffin, Yan Song, Hongbo Yang, et al.
 
The authors of the abstract conclude: 
There is considerable heterogeneity in post-HSCT maintenance therapy in patients with FLT3mut+ AML. Post-HSCT maintenance therapy, including FLT3-targeted post-HSCT maintenance therapy, may reduce the risk of clinical events without substantial increases in HRU.
 
————————————————————————————————————————————————————————
 
 
Abhishek Maiti, Courtney DiNardo, Tapan Kadia, et al.
 
The authors of the abstract conclude: 
DEC10-VEN shows superior outcomes compared to IC in older pts with AML in a PSM analysis. Benefits were most pronounced in pts at high risk of TRM.
 
————————————————————————————————————————————————————————
 
 
Amer M. Zeidan, Pierre Fenaux, Marco Gobbi, et al.
 
The authors of the abstract conclude: 
This is the largest comparison of clinical outcomes associated with AZA and DEC for patients with TN AML not eligible for intensive chemotherapy who were treated in the same prospective study. While patients were randomized between G and each of AZA and DEC separately with no direct randomization of AZA vs DEC, the patients’ characteristics were well balanced in patients randomized to the two HMA treatments. There were no significant differences in CR, overall CR, OS, or safety between AZA and DEC.
————————————————————————————————————————————————————————
 
 
Courtney DiNardo, Curtis Lachowiez, Gautam Borthakur, et al.
 
The authors of the abstract conclude: 
IVO+VEN AZA therapy is well tolerated and highly effective for patients with IDH1 mutated AML. Additional follow up and accrual is ongoing to better define tolerability, efficacy, and biomarkers of response.  Updated clinical data and additional translational analyses will be presented at the meeting. 
————————————————————————————————————————————————————————
 
 
Naval Daver, Monzr Al Malki, Adam Asch, et al.
 
The authors of the abstract conclude: 
Magrolimab is a novel macrophage targeting immunotherapy that with AZA is well tolerated and effective in AML patients unfit for intensive chemotherapy.  Durable efficacy is particularly encouraging in the TP53 mutant AML given the lack of effective therapies in this poor prognostic population.  Additional AML patients are enrolling (NCT03248479). Registrational approaches, particularly in TP53 mutant AML, are planned.   Additional patients, follow up and translational analyses will be reported at time of presentation. Funded by Forty Seven and the California Institute for Regenerative Medicine.   
 
MORE STATEMENTS ABOUT AML Visit vjhemonc.com